Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease (Q43732336)

26 November 2017

Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

26 November 2017

0 references

1 reference

R Dahl

1

1 reference

26 November 2017

L A Greefhorst

2

1 reference

26 November 2017

D Nowak

3

1 reference

26 November 2017

V Nonikov

4

1 reference

26 November 2017

A M Byrne

5

1 reference

26 November 2017

M H Thomson

6

1 reference

26 November 2017

D Till

7

1 reference

26 November 2017

G Della Cioppa

8

1 reference

26 November 2017

Formoterol in Chronic Obstructive Pulmonary Disease I Study Group

9

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

American Journal of Respiratory and Critical Care Medicine

26 November 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

26 November 2017

164

1 reference

26 November 2017

5

1 reference

26 November 2017

778-784

1 reference

Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force

26 November 2017

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.5.2007006

Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.5.2007006

Assessment of the clinical usefulness of nebulised ipratropium bromide in patients with chronic airflow limitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.5.2007006

Long-acting inhaled beta2-agonists in asthma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.5.2007006

Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.5.2007006

Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.5.2007006

Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.5.2007006

Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.5.2007006

Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.5.2007006

The challenge of providing better care for patients with chronic obstructive pulmonary disease: the poor relation of airways obstruction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.5.2007006

Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.5.2007006

Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.5.2007006

10.1164/AJRCCM.164.5.2007006

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference